Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4245) 4245
Book Chapter (31) 31
Newsletter (16) 16
Magazine Article (9) 9
Dissertation (6) 6
Newspaper Article (5) 5
Conference Proceeding (2) 2
Publication (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2788) 2788
life sciences & biomedicine (2656) 2656
humans (2283) 2283
male (2079) 2079
animals (2018) 2018
female (1554) 1554
benzoates - administration & dosage (1312) 1312
benzoates - pharmacology (1276) 1276
benzoates - therapeutic use (1188) 1188
biological and medical sciences (999) 999
rats (968) 968
medical sciences (855) 855
pharmacology & pharmacy (807) 807
adult (720) 720
middle aged (687) 687
mice (579) 579
pharmacology. drug treatments (491) 491
aged (471) 471
benzoates - adverse effects (466) 466
treatment outcome (412) 412
dose-response relationship, drug (408) 408
administration, oral (403) 403
telmisartan (391) 391
time factors (390) 390
benzimidazoles - administration & dosage (374) 374
benzimidazoles - therapeutic use (361) 361
hematology (332) 332
benzoates (317) 317
rats, sprague-dawley (314) 314
hypertension - drug therapy (309) 309
adolescent (303) 303
benzoates - pharmacokinetics (298) 298
analysis (293) 293
abridged index medicus (291) 291
blood pressure - drug effects (278) 278
chemistry (276) 276
benzimidazoles - pharmacology (271) 271
benzoates - chemistry (268) 268
cardiovascular system & cardiology (255) 255
drug therapy, combination (252) 252
rats, wistar (250) 250
hypertension (249) 249
physical sciences (248) 248
triazoles - therapeutic use (233) 233
disease models, animal (232) 232
benzoic acid (230) 230
sodium benzoate (229) 229
biochemistry & molecular biology (228) 228
child (225) 225
iron chelating agents - therapeutic use (216) 216
oncology (214) 214
neurosciences & neurology (209) 209
fundamental and applied biological sciences. psychology (208) 208
research (208) 208
neurosciences (200) 200
triazoles - administration & dosage (194) 194
angiotensin ii type 1 receptor blockers - therapeutic use (193) 193
benzoates - metabolism (193) 193
deferasirox (192) 192
pyrazoles - therapeutic use (191) 191
health aspects (186) 186
iron overload - drug therapy (183) 183
care and treatment (182) 182
double-blind method (182) 182
hydrazines - therapeutic use (182) 182
drug therapy (181) 181
angiotensin ii type 1 receptor blockers - administration & dosage (178) 178
toxicology (178) 178
peripheral vascular disease (173) 173
iron chelating agents - administration & dosage (170) 170
drug combinations (162) 162
medicine & public health (160) 160
young adult (159) 159
angiotensin ii type 1 receptor blockers - pharmacology (157) 157
child, preschool (156) 156
rodents (153) 153
estradiol - pharmacology (150) 150
antihypertensive agents - administration & dosage (147) 147
antihypertensive agents - therapeutic use (146) 146
receptors, thrombopoietin - agonists (146) 146
mice, inbred c57bl (144) 144
pyrazoles - administration & dosage (141) 141
estradiol benzoate (140) 140
monoterpenes (137) 137
purpura, thrombocytopenic, idiopathic - drug therapy (137) 137
medicine, research & experimental (134) 134
research & experimental medicine (133) 133
hydrazines - administration & dosage (131) 131
liver - metabolism (131) 131
aged, 80 and over (130) 130
eltrombopag (130) 130
pregnancy (128) 128
cell biology (127) 127
cells, cultured (126) 126
risk factors (126) 126
general & internal medicine (125) 125
endocrinology & metabolism (124) 124
benzoates - blood (123) 123
general pharmacology (122) 122
internal medicine (122) 122
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4026) 4026
German (104) 104
Japanese (103) 103
Russian (61) 61
French (41) 41
Chinese (35) 35
Italian (19) 19
Spanish (16) 16
Portuguese (9) 9
Polish (8) 8
Dutch (7) 7
Czech (4) 4
Danish (4) 4
Hungarian (3) 3
Bulgarian (2) 2
Norwegian (2) 2
Romanian (2) 2
Swedish (2) 2
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson’s disease after peripheral administration
by Dexter, David T and Dexter, David T and Statton, Sarah A and Statton, Sarah A and Whitmore, Charlotte and Whitmore, Charlotte and Freinbichler, Wolfhardt and Freinbichler, Wolfhardt and Weinberger, Peter and Weinberger, Peter and Tipton, Keith F and Tipton, Keith F and Della Corte, Laura and Della Corte, Laura and Ward, Roberta J and Ward, Roberta J and Crichton, Robert R and Crichton, Robert R
Journal of Neural Transmission, ISSN 0300-9564, 2/2011, Volume 118, Issue 2, pp. 223 - 231
Desferrioxamine | Deferasirox | Brain iron | Neurology | Neurosciences | Medicine & Public Health | Iron chelators | Deferiprone | Pharmacology/Toxicology | Psychiatry | Parkinson’s disease | Parkinson's disease | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Immunohistochemistry | Triazoles - administration & dosage | Injections, Intraventricular | Rats | Male | Deferoxamine - administration & dosage | Rats, Sprague-Dawley | Benzoates - administration & dosage | Brain - drug effects | Pyridones - administration & dosage | Animals | Microdialysis | Sorbic Acid - administration & dosage | Free Radicals - analysis | Parkinsonian Disorders - drug therapy | Iron Chelating Agents - administration & dosage | Neuroprotective Agents - administration & dosage | Iron | Hydroxides | Neurons | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC
by Mohammad, Helai P and Smitheman, Kimberly N and Kamat, Chandrashekhar D and Soong, David and Federowicz, Kelly E and Van Aller, Glenn S and Schneck, Jess L and Carson, Jeffrey D and Liu, Yan and Butticello, Michael and Bonnette, William G and Gorman, Shelby A and Degenhardt, Yan and Bai, Yuchen and McCabe, Michael T and Pappalardi, Melissa B and Kasparec, Jiri and Tian, Xinrong and McNulty, Kenneth C and Rouse, Meagan and McDevitt, Patrick and Ho, Thau and Crouthamel, Michelle and Hart, Timothy K and Concha, Nestor O and McHugh, Charles F and Miller, William H and Dhanak, Dashyant and Tummino, Peter J and Carpenter, Christopher L and Johnson, Neil W and Hann, Christine L and Kruger, Ryan G
Cancer cell, ISSN 1535-6108, 07/2015, Volume 28, Issue 1, pp. 57 - 69
Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Lung Neoplasms - drug therapy | Histone Demethylases - antagonists & inhibitors | Humans | Molecular Sequence Data | Lung Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Histone Demethylases - genetics | Small Cell Lung Carcinoma - drug therapy | Enzyme Inhibitors - administration & dosage | Cyclopropanes - administration & dosage | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Cyclopropanes - pharmacology | Lung Neoplasms - genetics | Administration, Oral | Enzyme Inhibitors - pharmacology | Small Cell Lung Carcinoma - genetics | Benzoates - administration & dosage | Xenograft Model Antitumor Assays | Small Cell Lung Carcinoma - pathology | Animals | Benzoates - pharmacology | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | DNA Methylation - drug effects | Epigenetic inheritance | Lung cancer | DNA | Lysine | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Hematopoietic growth factors in myelodysplastic syndromes
by Steensma, David P
Seminars in oncology, ISSN 0093-7754, 10/2011, Volume 38, Issue 5, pp. 635 - 647
Life Sciences & Biomedicine | Oncology | Science & Technology | Recombinant Proteins - therapeutic use | Benzoates - adverse effects | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Erythropoietin - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Erythropoietin - adverse effects | Thrombopoietin - therapeutic use | Recombinant Proteins - adverse effects | Thrombopoietin - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Filgrastim | Patient Selection | Receptors, Fc - therapeutic use | Erythropoietin - analogs & derivatives | Drug-Related Side Effects and Adverse Reactions | Colony-Stimulating Factors - adverse effects | Epoetin Alfa | Hydrazines - administration & dosage | Myelodysplastic Syndromes - drug therapy | Recombinant Fusion Proteins - administration & dosage | Colony-Stimulating Factors - therapeutic use | Pyrazoles - adverse effects | Granulocyte Colony-Stimulating Factor - adverse effects | Erythropoietin - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Hydrazines - therapeutic use | Hematinics - therapeutic use | Polyethylene Glycols | Hematinics - adverse effects | Granulocyte Colony-Stimulating Factor - therapeutic use | Hematinics - administration & dosage | Recombinant Proteins - administration & dosage | Benzoates - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects | Pyrazoles - administration & dosage | Thrombopoietin - adverse effects | Receptors, Fc - administration & dosage | Darbepoetin alfa | Colony-Stimulating Factors - administration & dosage | Granulocyte Colony-Stimulating Factor - administration & dosage | Hydrazines - adverse effects
Journal Article
Details down arrow
4. Full Text Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial
by Webster, Ruth and Salam, Abdul and de Silva, H. Asita and Selak, Vanessa and Stepien, Sandrine and Rajapakse, Senaka and Amarasekara, Stanley and Amarasena, Naomali and Billot, Laurent and de Silva, Arjuna P and Fernando, Mervyn and Guggilla, Rama and Jan, Stephen and Jayawardena, Jayanthimala and Maulik, Pallab K and Mendis, Sepalika and Mendis, Suresh and Munasinghe, Janake and Naik, Nitish and Prabhakaran, Dorairaj and Ranasinghe, Gotabaya and Thom, Simon and Tisserra, Nirmali and Senaratne, Vajira and Wijekoon, Sanjeewa and Wijeyasingam, Santharaj and Rodgers, Anthony and Patel, Anushka and TRIUMPH Study Grp and TRIUMPH Study Group and for the TRIUMPH Study Group
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 08/2018, Volume 320, Issue 6, pp. 566 - 579
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Sri Lanka | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Amlodipine - adverse effects | Hypertension - drug therapy | Male | Chlorthalidone - adverse effects | Benzoates - administration & dosage | Telmisartan | Dose-Response Relationship, Drug | Medication Adherence | Benzimidazoles - administration & dosage | Chlorthalidone - administration & dosage | Adult | Female | Potassium - blood | Aged | Blood Pressure - drug effects | Benzimidazoles - adverse effects | Amlodipine - administration & dosage | Drug Combinations | Hypertension | Control | Antihypertensive drugs | Dosage and administration | Blood pressure | Drug therapy | Health aspects | Drugs | Global health | Therapy | Kidneys | Medical treatment | Diabetes mellitus | Clinical trials | Patients | Blood | Pain | Syncope | Adults | Kidney diseases | Drug dosages | Mercury | Public health | Index Medicus | Abridged Index Medicus | Original Investigation | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia
by Ehrlich, Lori A and Kwitkowski, Virginia E and Reaman, Gregory and Ko, Chia‐Wen and Nie, Lei and Pazdur, Richard and Farrell, Ann T
Pediatric blood & cancer, ISSN 1545-5009, 12/2017, Volume 64, Issue 12, pp. e26657 - n/a
immune thrombocytopenic purpura | Promacta | eltrombopag | pediatric | Pediatrics | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Thrombocythemia, Essential - drug therapy | Hydrazines - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | United States | Humans | Child, Preschool | Infant | Male | Drug Approval | Benzoates - administration & dosage | Pyrazoles - administration & dosage | Adolescent | Female | Child | Chronic Disease | Hydrazines - administration & dosage | United States Food and Drug Administration | Thrombocytopenia | Children | Health aspects | Drug approval | Corticoids | Regulatory agencies | Immunoglobulins | Corticosteroids | Clinical trials | FDA approval | Patients | Splenectomy | Antidepressants | Risk assessment | Age | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Pulmonary administration of Am80 regenerates collapsed alveoli
by Sakai, Hitomi and Horiguchi, Michiko and Ozawa, Chihiro and Akita, Tomomi and Hirota, Keiji and Shudo, Koichi and Terada, Hiroshi and Makino, Kimiko and Kubo, Hiroshi and Yamashita, Chikamasa
Journal of controlled release, ISSN 0168-3659, 12/2014, Volume 196, pp. 154 - 160
Alveolar regeneration | Chronic obstructive pulmonary disease | Pulmonary administration | Am80 (Tamibarotene) | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Epithelial Cells - drug effects | Humans | Pulmonary Emphysema - pathology | Pulmonary Emphysema - drug therapy | Receptors, Retinoic Acid - metabolism | Pulmonary Disease, Chronic Obstructive - pathology | Benzoates - administration & dosage | Regeneration - drug effects | Animals | Tetrahydronaphthalenes - administration & dosage | Cell Differentiation - drug effects | Tetrahydronaphthalenes - pharmacology | Pulmonary Disease, Chronic Obstructive - chemically induced | Benzoates - pharmacology | Pancreatic Elastase | Pulmonary Alveoli - drug effects | Stem Cells - drug effects | Mice | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | DNA microarrays | Analysis | Stem cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke
by Sacco, Ralph L and Diener, Hans-Christoph and Yusuf, Salim and Cotton, Daniel and Ôunpuu, Stephanie and Lawton, William A and Palesch, Yuko and Martin, Reneé H and Albers, Gregory W and Bath, Philip and Bornstein, Natan and Chan, Bernard P.L and Chen, Sien-Tsong and Cunha, Luis and Dahlöf, Björn and De Keyser, Jacques and Donnan, Geoffrey A and Estol, Conrado and Gorelick, Philip and Gu, Vivian and Hermansson, Karin and Hilbrich, Lutz and Kaste, Markku and Lu, Chuanzhen and Machnig, Thomas and Pais, Prem and Roberts, Robin and Skvortsova, Veronika and Teal, Philip and Toni, Danilo and VanderMaelen, Cam and Voigt, Thor and Weber, Michael and Yoon, Byung-Woo and PRoFESS Study Grp and PRoFESS Study Group and Sahlgrenska akademin and Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin and Institute of Medicine, Department of Emergeny and Cardiovascular Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The New England journal of medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
ACTIVE CONTROLLED-TRIALS | HIGH-RISK PATIENTS | TICLOPIDINE | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ARTERIAL ORIGIN ESPRIT | CEREBRAL-ISCHEMIA | UMCG Approved | NON-INFERIORITY TRIALS | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Neurology | Biological and medical sciences | General aspects | Vascular diseases and vascular malformations of the nervous system | Medical sciences | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Inhaled Agonists of Soluble Guanylate Cyclase Induce Selective Pulmonary Vasodilation
by Evgenov, Oleg V and Kohane, Daniel S and Bloch, Kenneth D and Stasch, Johannes-Peter and Volpato, Gian P and Bellas, Evangelia and Evgenov, Natalia V and Buys, Emmanuel S and Gnoth, Mark J and Graveline, Amanda R and Liu, Rong and Hess, Dean R and Langer, Robert and Zapol, Warren M
American journal of respiratory and critical care medicine, ISSN 1073-449X, 12/2007, Volume 176, Issue 11, pp. 1138 - 1145
BAY 41-2272 | BAY 58-2667 | Pulmonary hypertension | BAY 41-8543 | Soluble guanylate cyclase | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Pharmacology. Drug treatments | Biological and medical sciences | Intensive care medicine | Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases | Medical sciences | Respiratory system | Pneumology | Oxadiazoles - administration & dosage | Injections, Intravenous | Nitric Oxide - pharmacology | Purinones - administration & dosage | Dose-Response Relationship, Drug | Quinoxalines - pharmacology | Oxadiazoles - pharmacology | Lung - metabolism | Pyrazoles - pharmacology | Powders | Pyridines - administration & dosage | Quinoxalines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Administration, Inhalation | Morpholines - pharmacology | Phosphodiesterase Inhibitors - pharmacology | Soluble Guanylyl Cyclase | Receptors, Cytoplasmic and Nuclear - agonists | Pyrimidines - pharmacology | Nitric Oxide - administration & dosage | Benzoates - administration & dosage | Particle Size | Phosphodiesterase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Animals | Cyclic GMP - metabolism | Guanylate Cyclase | Lung - drug effects | Aerosols | Benzoates - pharmacology | Purinones - pharmacology | Sheep | Pulmonary Circulation - drug effects | Pyridines - pharmacology | Vasodilation - drug effects | Drug Combinations | Index Medicus | Abridged Index Medicus | H. Pulmonary Vascular Disease | soluble guanylate cyclase | pulmonary hypertension
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
by Mann, Johannes FE, Prof and Schmieder, Roland E, Prof and McQueen, Matthew, Prof and Dyal, Leanne, MSc and Schumacher, Helmut, MD and Pogue, Janice, PhD and Wang, Xingyu, PhD and Maggioni, Aldo, MD and Budaj, Andrzej, MD and Chaithiraphan, Suphachai, Prof and Dickstein, Kenneth, MD and Keltai, Matyas, Prof and Metsärinne, Kaj, MD and Oto, Ali, Prof and Parkhomenko, Alexander, MD and Piegas, Leopoldo S, MD and Svendsen, Tage L, MD and Teo, Koon K, Prof and Yusuf, Salim, Prof and on behalf of the ONTARGET investigators and ONTARGET Investigators and ONTARGET investigators
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9638, pp. 547 - 553
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Ramipril - administration & dosage | Proteinuria - chemically induced | Cardiovascular Diseases - complications | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Benzimidazoles - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Benzimidazoles - therapeutic use | Kidney - drug effects | Double-Blind Method | Diabetes Mellitus - drug therapy | Proteinuria - metabolism | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Creatinine - urine | Benzoates - administration & dosage | Creatinine - blood | Aged | Urine | Drugs | Studies | Kidneys | Disease | Clinical trials | Risk | ACE inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow